With respect to the clinical implications, our study signifies that measuring TG2 expressions could facilitate the evaluation of the severity of CKD progression and presents the detailed beneficial phenomenon that results from pharmacologic TG2 inhibition in kidney TECs. Here, TGM2 is linked to chronic kidney disease.